Johnson & Johnson has had frequent executive changes in recent years, not only in the innovative pharmaceutical industry, but also in the medical technology department. At least nine executive changes have been reported since 2023.
Recently, Enovis, a global orthopedic giant, announced the appointment of Tim Czartoski as president of its U.S. surgical and global products and supporting technologies business. Tim Czartoski previously worked in the DePuy Synthes orthopedic business unit of Johnson & Johnson Medical Technology.
Tim Czartoski is a very experienced veteran in the medical field. He has more than 20 years of experience in the medical technology industry, especially in the orthopedic business. Tim Czartoski has held several key positions at Johnson & Johnson, leading the growth of Johnson & Johnson's business.

Looking back at Tim Czartoski's career at Johnson & Johnson, he has held several positions in the DePuy Synthes orthopedic business unit of Johnson & Johnson Medical Technologies, and most recently served as President of the United States for the DePuy Synthes orthopedic business unit of Johnson & Johnson Medical Technologies. Under

his leadership, DePuy Synthes operated joint reconstruction, trauma, spine, digital technology and CMF businesses in the United States. In addition, Czartoski also served as President of DePuy Synthes' global joint reconstruction business.

In recent years, Johnson & Johnson has been making big moves. In March 2022, the medical device business was officially renamed Johnson & Johnson Medical Technologies; on September 14, 2023, Johnson & Johnson announced a brand renewal, replacing the brand logo that had been used for 135 years, launching a newly designed logo, and highlighting the abbreviated brand logo "J&J" in application scenarios such as digital interfaces.

At the same time, Johnson & Johnson also announced that it would integrate its two major businesses, medical technology and pharmaceuticals, under the name of Johnson & Johnson, in order to establish a closer connection between the two market segments and the Johnson & Johnson brand. The pharmaceutical business Janssen will be renamed Johnson & Johnson Innovative Pharmaceuticals, while Johnson & Johnson Medical Technologies will remain unchanged.

Since Johnson & Johnson's drastic reforms and renewals, its internal policies have also undergone a "major blood transfusion". The blood transfusion is not only reflected in the changes in senior management, but the internal structure has also been on the road to change.

Recently, Johnson & Johnson sent a message that it is simplifying and reshaping its brand, announcing that five medical device businesses will be incorporated under the name of Johnson & Johnson Medical Technologies. Ethicon, Depuy Synthes, Biosense Webster, Abiomed and Cerenovus no longer exist as independent entities, but Johnson & Johnson announced no changes to the product lineup. From now on, these businesses will be grouped under the Johnson & Johnson Medical Technologies brand name. This move is also the next step in the brand and visual identity refresh announced by Johnson & Johnson last fall, and this change will not affect the medical technology products and solutions currently offered to customers.

Today, Tim Czartoski takes on a new role. After being named president of Enovis' U.S. Surgical and Global Products and Support Technologies business, he will be responsible for the company's U.S. surgical business, including the global surgical product engine and supporting technologies, and will report to Louie Vogt, president of Enovis's Reconstructive Business Group.
Enovis may be relatively unfamiliar to the domestic market because it has not yet entered the domestic market. However, Enovis itself is also relatively strong. It is a global medical technology company that focuses on innovation and solutions in the field of orthopedics. It currently has more than 40 years of industry experience. Through continuous acquisitions and product development, Enovis has occupied an important position in the global orthopedic market.

After years of development, Enovis's business segments are very broad, including medical devices, surgical instruments, ankle and foot solutions, supports and brackets, rehabilitation sciences, regenerative sciences, foot care solutions and medical solutions. In addition, the product pipeline is also very comprehensive, covering a wide range of orthopedic implants, surgical techniques and rehabilitation solutions, including joint replacements, trauma repair, spinal treatment and sports medicine.

The following are Enovis' products:
Medical Devices
ARVIS® Augmented Reality System: a wearable, self-contained system that provides real-time, hands-free surgical guidance;
EMPOWR 3D Knee®: The only dual-rotation knee system on the market;
AltiVate Reverse® Shoulder: Market leading system based on the principles of the RSP® shoulder design.
Ankle & Foot Solutions
DynaNail Helix™: An innovative solution for the ankle and foot
STAR® Ankle: a non-fixed implant for replacing painful joints;
Arsenal Plating System™: Variable angle locking technology and dual lead screws for the ankle and foot.
Supports and brackets
DonJoy®: Pioneer in functional knee braces founded over 40 years ago;
Aircast®: provides support and rehabilitation products for the knees, ankles, elbows, back, wrists, shoulders, etc.;
ProCare®: offers a comprehensive line of products for upper and lower extremities;
Exos®: A revolutionary plasticity technology that adjusts and reshapes solutions for the upper and lower extremities and spine.
Rehabilitation Science
Chattanooga®, LightForce®, Companion®, Compex® and Pegasus™: providing a broad portfolio of products for rehabilitation, pain management and healing;
Companion® Animal Health: Focused on laser therapy, regenerative medicine and point-of-care diagnostics that improve the lives of pet patients.
Regenerative Science
CMF Bone Growth Stimulation Technology: Providing medical professionals with effective tools for treating non-union fractures and lumbar fusion surgeries.

Foot Care Solutions
Dr. Comfort®: Providing quality, comfort and stylish solutions for those with diabetes or other foot conditions;
Elastic Therapy (ETI): an FDA-registered manufacturer of compression products used to treat and prevent venous and lymphatic disorders.
Medical Solutions
MotionMD®: an automated and scalable platform that improves efficiency and compliance while enhancing the patient and user experience;
OaraScore®: A clinically validated risk stratification tool for total joint replacement designed to help healthcare professionals determine if a patient is a good candidate for surgery in an outpatient setting.
In addition, Enovis had several innovative products unveiled at the 2024 AAOS Annual Meeting held in March of this year, including the EMPOWR 3D Knee®, the first and only product on the market with a dual-axis total knee design that better simulates the movement of the natural knee joint.

The addition of Tim Czartoski is undoubtedly a great help to Enovis. Returning to Enovis itself, its own strength should not be underestimated. Its performance in 2023 was also quite impressive, with revenue of US$1.707 billion, up 9.22% year-on-year. It can be seen that Enovis' performance is also growing steadily. We expect that Enovis will be able to deliver a more dazzling answer in the second half of the year after Tim Czartoski joins.

https://news.yaozh.com/archive/44224.html